Tela Bio (TELA)CEO bought ~$10K

~$10K

Approx. value · 15K sh @ $0.6978

520K

Holds after · shares reported

Traded

Aug 14, 2026

Filed

Aug 18, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Aug 3, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On August 3, 2026, the Board of Directors (the “ Board ”) of TELA Bio, Inc. (the “ Company ”) determined that, Antony Koblish will no longer serve as the Company’s Chief Executive Officer and the principal executive officer, effective on August 3, 2026 (the “ Effective Date ”).”
2. Aug 3, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On August 7, 2026 (the “ Effective Date ”), the Company and Mr. Koblish entered into a Separation Agreement and General Release (the “ Separation Agreement ”).”
3. Aug 10, 2026Company filing · Form 8-K · ResultsReported its results
4. Aug 14, 2026 · this disclosureInsider · 14 days before an 8-KCEO purchased ~$10K of TELA shares in the open market

What came next

1. Aug 17, 2026Insider · 11 days before an 8-KCEO purchased ~$8.3K of TELA shares in the open market
2. Aug 28, 2026Company filing · Form 8-K · Restructuring, Executive changeAnnounced job cuts, closures or a restructuring, and changed a top executive or board member (and 1 more item)“Effective on August 31, 2026, Roberto Cuca stepped down from his position as the Company’s Chief Financial Officer, Chief Operating Officer, Corporate Secretary and principal financial officer.”
3. Sep 14, 2026Insider · 1 day before an 8-KDirector purchased ~$26K of TELA shares in the open market
4. Sep 15, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“As previously disclosed, on March 17, 2026, TELA Bio, Inc. (the “ Company ”) received a letter from the Listing Qualifications Department (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Market, as the minimum bid price of the Company’s common…”
5. Sep 15, 2026InsiderDirector purchased ~$53K of TELA shares in the open market
6. Sep 16, 2026InsiderDirector purchased ~$58K of TELA shares in the open market
7. Sep 17, 2026InsiderDirector purchased ~$31K of TELA shares in the open market
8. Sep 28, 2026Company filing · Form 8-K · Material agreementSigned an important agreement

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Tela Bio

For Tela Bio, OQRO holds 6 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its TELA page.

Other recent filings by Heather C Getz, Chief Executive Officer

• SEC Form 4 at Tela Bio (TELA)Aug 20, 2026
• SEC Form 4 at Butterfly Network (BFLY)May 7, 2025
• SEC Form 4 at Butterfly Network (BFLY)Dec 26, 2024

The full history of Heather C Getz, Chief Executive Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Tela Bio

• SEC Form 4Sep 19, 2026
• SEC Form 4Sep 19, 2026
• SEC Form 4Sep 17, 2026
• SEC Form 4Sep 17, 2026
• SEC Form 4Aug 20, 2026
• SEC Form 4Nov 18, 2025

Everything OQRO holds on this company is on its TELA page.